Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Clinuvel Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 2/4
Clinuvel Pharmaceuticals' CEO'su Philippe Wolgen, Nov2005 tarihinde atandı, in görev süresi 18.92 yıldır. in toplam yıllık tazminatı A$ 3.74M olup, şirket hissesi ve opsiyonları dahil olmak üzere 47.2% maaş ve 52.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 6.86% ine doğrudan sahiptir ve bu hisseler A$ 49.73M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.8 yıl ve 5 yıldır.
Anahtar bilgiler
Philippe Wolgen
İcra Kurulu Başkanı
AU$3.7m
Toplam tazminat
| CEO maaş yüzdesi | 47.2% |
| CEO görev süresi | 18.9yrs |
| CEO sahipliği | 6.9% |
| Yönetim ortalama görev süresi | less than a year |
| Yönetim Kurulu ortalama görev süresi | 5yrs |
Son yönetim güncellemeleri
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | AU$4m | AU$2m | AU$36m |
| Mar 31 2024 | n/a | n/a | AU$33m |
| Dec 31 2023 | n/a | n/a | AU$30m |
| Sep 30 2023 | n/a | n/a | AU$30m |
| Jun 30 2023 | AU$6m | AU$2m | AU$31m |
| Mar 31 2023 | n/a | n/a | AU$29m |
| Dec 31 2022 | n/a | n/a | AU$26m |
| Sep 30 2022 | n/a | n/a | AU$24m |
| Jun 30 2022 | AU$7m | AU$1m | AU$21m |
| Mar 31 2022 | n/a | n/a | AU$22m |
| Dec 31 2021 | n/a | n/a | AU$24m |
| Sep 30 2021 | n/a | n/a | AU$24m |
| Jun 30 2021 | AU$5m | AU$2m | AU$25m |
| Mar 31 2021 | n/a | n/a | AU$23m |
| Dec 31 2020 | n/a | n/a | AU$21m |
| Sep 30 2020 | n/a | n/a | AU$18m |
| Jun 30 2020 | AU$3m | AU$2m | AU$15m |
| Mar 31 2020 | n/a | n/a | AU$15m |
| Dec 31 2019 | n/a | n/a | AU$15m |
| Sep 30 2019 | n/a | n/a | AU$16m |
| Jun 30 2019 | AU$1m | AU$894k | AU$18m |
| Mar 31 2019 | n/a | n/a | AU$17m |
| Dec 31 2018 | n/a | n/a | AU$16m |
| Sep 30 2018 | n/a | n/a | AU$15m |
| Jun 30 2018 | AU$2m | AU$818k | AU$13m |
Tazminat ve Piyasa: Philippe 'nin toplam tazminatı ($USD 2.58M ), Australian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 899.18K ).
Tazminat ve Kazançlar: Philippe 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Philippe Wolgen (61 yo)
18.9yrs
Görev süresi
AU$3,742,412
Tazminat
Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, MD & Director | 18.9yrs | AU$3.74m | 6.86% A$ 48.3m | |
| Chief Scientific Officer | 12.1yrs | AU$782.61k | 0.38% A$ 2.7m | |
| Chief Financial Officer | less than a year | Veri yok | Veri yok | |
| Chief Operations Officer | no data | Veri yok | Veri yok | |
| Head of Australian Operations & Investor Relations | no data | Veri yok | Veri yok | |
| Senior Vice President of Regulatory Affairs | less than a year | Veri yok | Veri yok | |
| Head of Quality Assurance & Drug Safety | less than a year | Veri yok | Veri yok | |
| Company Secretary | less than a year | Veri yok | Veri yok |
0.8yrs
Ortalama Görev Süresi
Deneyimli Yönetim: CUV 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, MD & Director | 19yrs | AU$3.74m | 6.86% A$ 48.3m | |
| Non-Executive Director | 17.7yrs | AU$85.00k | 0.23% A$ 1.6m | |
| Non-Executive Director | less than a year | Veri yok | Veri yok | |
| Non-Executive Director | less than a year | Veri yok | Veri yok | |
| Non-Executive Director | 5.1yrs | AU$80.00k | 0.00084% A$ 5.9k | |
| Non-Executive Chairman | 4.9yrs | AU$91.67k | 0.0063% A$ 44.3k | |
| Non-Executive Director | 6.8yrs | AU$75.00k | 0.011% A$ 77.5k | |
| Non-Executive Director | less than a year | Veri yok | Veri yok |
5.0yrs
Ortalama Görev Süresi
Deneyimli Yönetim Kurulu: CUV 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5 yıldır).